|
|
Volumn 4, Issue 5, 2003, Pages 306-309
|
|
Cannabis-based medicines - GW Pharmaceuticals. High CBD, high THC, medicinal cannabis - GW Pharmaceuticals, THC:CBD
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANNABIDIOL;
CANNABINOID;
CANNABIS;
CANNABIS DERIVATIVE;
NARCOTIC ANALGESIC AGENT;
PLANT MEDICINAL PRODUCT;
TETRAHYDROCANNABINOL;
ANTIINFLAMMATORY ACTIVITY;
ANTINOCICEPTION;
ARTICLE;
BRACHIAL PLEXUS INJURY;
CANCER PAIN;
CENTRAL NERVOUS SYSTEM DISEASE;
CEREBROVASCULAR ACCIDENT;
CHEMISTRY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG DELIVERY SYSTEM;
DRUG FORMULATION;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
DYSTONIA;
ENTERITIS;
EPILEPSY;
EUPHORIA;
HEAD INJURY;
HUMAN;
MULTIPLE SCLEROSIS;
NEUROLOGIC DISEASE;
NEUROPATHIC PAIN;
PAIN;
PERIPHERAL NERVE INJURY;
PERIPHERAL NEUROPATHY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PHYTOTHERAPY;
PRIORITY JOURNAL;
PSYCHOSIS;
RHEUMATOID ARTHRITIS;
SCHIZOPHRENIA;
SIDE EFFECT;
SPINA BIFIDA;
SPINAL CORD INJURY;
STROKE;
SUBLINGUAL DRUG ADMINISTRATION;
VERTIGO;
|
|
EID: 0141706956
PISSN: 11745886
EISSN: None
Source Type: Journal
DOI: 10.2165/00126839-200304050-00005 Document Type: Article |
|
Times cited : (34)
|
|
References (4)
|
